Drug intelligence / Profile preview

HRS-3005

Development stage: Phase 1
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HRS-3005 is an investigational small molecule inhibitor of B-cell lymphoma 2 (BCL-2) being developed by Jiangsu HengRui Medicine. BCL-2 is a pro-survival protein that is frequently overexpressed in various B-cell malignancies, where it prevents apoptosis (programmed cell death) of cancer cells. By selectively binding to and inhibiting BCL-2, HRS-3005 aims to restore the apoptotic pathway and induce cell death in malignant B-cells. It is currently being evaluated in Phase I clinical trials for the treatment of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas. As a next-generation BCL-2 inhibitor, it is designed to offer high selectivity and potency while minimizing off-target effects.

Beyond the preview

Go deeper on HRS-3005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS-3005.

Explore the full profile